Featured Research

from universities, journals, and other organizations

Tau drug heads into phase 3 trials in frontotemporal dementia, Alzheimer's

Date:
October 5, 2012
Source:
Alzheimer Research Forum Foundation
Summary:
A small company with roots in Singapore and Scotland plans to test a relatively unknown compound in clinical trials for a type of dementia that strongly affects behavior.

Remberฎ -- the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease -- has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).

TauRx Therapeutics, a Singaporean-Scottish biotech company, reformulated Remberฎ to improve absorption and tolerability, and will test its modified oral compound, LMTX, in bvFTD patients at 25 to 30 sites worldwide. Pending ethics review and approvals, the 12-month bvFTD trial is expected to begin enrolling in November or December. The company also plans to launch two Phase 3 trials in AD in late 2012.

The TauRx molecule has roused researchers' curiosity on a number of fronts. It is believed to be the only drug in clinical testing that breaks up aggregates of tau, the protein that forms neurofibrillary tangles in Alzheimer's and other neurodegenerative diseases. Even more unusual, it has reached Phase 3 with hardly any published preclinical data. Aside from several talks and posters presented at the International Conferences on Alzheimer's Disease in Chicago and Vienna, which Alzforum reported in 2008 and 2009, very little data on Rember or LMTX is in the public domain. Moreover, scientists had concerns about the design and analysis of the company's earlier Phase 2 trial in AD, some of which are addressed in the upcoming Phase 3 studies. A recent Alzforum story and Q&A with TauRx CEO Claude Wischik describe these developments.


Story Source:

The above story is based on materials provided by Alzheimer Research Forum Foundation. Note: Materials may be edited for content and length.


Cite This Page:

Alzheimer Research Forum Foundation. "Tau drug heads into phase 3 trials in frontotemporal dementia, Alzheimer's." ScienceDaily. ScienceDaily, 5 October 2012. <www.sciencedaily.com/releases/2012/10/121005134627.htm>.
Alzheimer Research Forum Foundation. (2012, October 5). Tau drug heads into phase 3 trials in frontotemporal dementia, Alzheimer's. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2012/10/121005134627.htm
Alzheimer Research Forum Foundation. "Tau drug heads into phase 3 trials in frontotemporal dementia, Alzheimer's." ScienceDaily. www.sciencedaily.com/releases/2012/10/121005134627.htm (accessed August 27, 2014).

Share This




More Mind & Brain News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Alice in Wonderland Syndrome

Alice in Wonderland Syndrome

Ivanhoe (Aug. 27, 2014) — It’s an unusual condition with a colorful name. Kids with “Alice in Wonderland” syndrome see sudden distortions in objects they’re looking at or their own bodies appear to change size, a lot like the main character in the Lewis Carroll story. Video provided by Ivanhoe
Powered by NewsLook.com
Stopping Schizophrenia Before Birth

Stopping Schizophrenia Before Birth

Ivanhoe (Aug. 27, 2014) — Scientists have long called choline a “brain booster” essential for human development. Not only does it aid in memory and learning, researchers now believe choline could help prevent mental illness. Video provided by Ivanhoe
Powered by NewsLook.com
Personalized Brain Vaccine for Glioblastoma

Personalized Brain Vaccine for Glioblastoma

Ivanhoe (Aug. 27, 2014) — Glioblastoma is the most common and aggressive brain cancer in humans. Now a new treatment using the patient’s own tumor could help slow down its progression and help patients live longer. Video provided by Ivanhoe
Powered by NewsLook.com
Brain Surgery in 3-D

Brain Surgery in 3-D

Ivanhoe (Aug. 27, 2014) — Neurosurgeons now have a new approach to brain surgery using the same 3D glasses you’d put on at an IMAX movie theater. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins